drugset / Trial / NCT03413306
Eltrombopag+hATG+CsA vs. hATG+CsA in Children With Severe AA
Phase 3
Unknown
100 enrolled
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
RandomizedParallel-groupOpen-labelTreatment
Summary
The analysis of our own clinical data suggests that majority of the hematologic responses observed after the course of h-ATG/CsA is partial, and about 10% tend to have cyclosporine dependence. The aim of the current study is to improve the rate and the quality of hematologic response as well as to prevent delayed complications such as relapse and clonal progression by means of adding eltrombopag to standard immunosuppressive therapy
Timeline
- Start
- 2016-12-10
- Primary completion
- 2022-10-20
- Completion
- 2022-10-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eltrombopag | Small molecule | — | Oral |
| Background | ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | Protein / enzyme biologic | — | — |
| Background | Cyclosporine | Peptide | — | — |